Blog

Over the life of a study, the amount of time and resources spent on changes to a system can significantly impact the study – but do they have to?

An RTSM has critical functions with direct patient impact. As trials grow in complexity, adopting modern tech is inevitable for companies hoping to keep up.

4G Clinical partnered with SCRS to host their first Site Advisory Group for RTSM/IRT systems, where sites and sponsors gathered to discuss, among many other topics, what sites want from their IRT/RTSM.

Did you know that Phase 1 trials can be even more complex than their Phase 2 and 3 counterparts? Don't let scale be the determining factor in choosing to leverage an RTSM. Here are 5 questions to ask when you consider an RTSM for your next Phase 1 study.

4G Clinical partnered with SCRS to host their first Site Advisory Group for RTSM/IRT systems, where sites and sponsors gathered to discuss, among many other topics, how sponsors can become more site-centric.

Having an IRT/RTSM for your IITs will help with supply chain management since IITs traditionally draw from the same pool of drugs as manufacturer-sponsored studies. See how.

In the 4th Debunking Clinical Trial Myths video you'll hear from Joseph Kim from Eli Lilly and Company on the reason for strict enrollment criteria.

On Wednesday, June 26th, 4G Clinical co-founders David Kelleher and Ed Tourtellotte were recognized as finalists for EY’s Entrepreneur Of The Year ®2019 Award for the New England region. An impressive group of unstoppable entrepreneurs from 36 companies across many industries celebrated entrepreneurship throughout the evening at the Westin Waterfront hotel in Boston.

In the third episode of our Debunking Clinical Trial Myths video series you will hear from T.J. Sharpe, a Melanoma Survivor, patient advisor and previous trial participant on the use of placebos in clinical studies.